• Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=15900046).
  

PubMed=8882729; DOI=10.1093/oxfordjournals.jbchem.a021246
Satoh A., Takayama E., Kojima K., Ogawa H., Yamori T., Sato S., Kawaguchi T., Tsuruo T., Katsura Y., Kina T., Matsumoto I.
Expression of carbohydrate-binding protein p33/41 in human tumor cell lines.
J. Biochem. 119:346-353(1996)

PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234
Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y., Yamori T.
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.
Mol. Cancer Ther. 4:399-412(2005)

PubMed=15900046; DOI=10.1093/jnci/dji133
Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y., Yamazaki K., Hamada J.-i., Tada M., Moriuchi T., Ishikawa Y., Kato Y., Tomoda H., Yamori T., Tsuruo T.
p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target.
J. Natl. Cancer Inst. 97:765-777(2005)

PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017
Kong D.-X., Yamori T.
JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
Bioorg. Med. Chem. 20:1947-1951(2012)